Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urocell for stress urinary incontinence due to intrinsic sphincter deficiency
NL-OMON30498Phase 2Withdrawn
- Sponsor
- Innovacell
- Start
- Jun 2007
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Urocell in stress urinary incontinence (SUI) and Intrinsic Sphincter Deficiency (ISD), sponsored by Innovacell. Primary endpoint: Safety and tolerability. Planned start Jun 2007; status: withdrawn.
02
Drugs
Urocell
03
Conditions
stress urinary incontinence (SUI)Intrinsic Sphincter Deficiency (ISD)
Beyond the preview
Go deeper on NL-OMON30498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30498.